Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 32Filgrastim 18Irinotecan 15Topotecan 14Temozolomide 13Vincristine 12Peripheral Blood Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12Etoposide 12Melphalan 11fludarabine 10Carboplatin 9dinutuximab 8Isotretinoin 8Interleukin-2 8Busulfan 8humanized 3F8 anti-GD2 monoclonal antibody 7aldesleukin 7Doxorubicin 73-Iodobenzylguanidine 7sargramostim 6fludarabine phosphate 6Vorinostat 6Zoledronic Acid 5Stem Cell Transplantation 5Cisplatin 5etoposide phosphate 4Ipilimumab 4Drug Therapy 4ribociclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroblastoma × Cytokines × Clear all
NCT01576692 2018-11-15

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

St. Jude Children's Research Hospital

Phase 1 Completed
34 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡